These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28427074)

  • 1. Enzymatic Vitreolysis for Vitreomacular Traction in Diabetic Retinopathy.
    Rizzo S; Bacherini D
    Dev Ophthalmol; 2017; 60():160-164. PubMed ID: 28427074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction.
    Elbendary AM; Elwan MM; Azzam HA; Eldeeb DR
    Curr Eye Res; 2011 Jun; 36(6):534-9. PubMed ID: 21591862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
    Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
    Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic vitreolysis with ocriplasmin: rationale for use and therapeutic potential in vitreo-retinal disorders.
    Khoshnevis M; Sebag J
    BioDrugs; 2015 Apr; 29(2):103-12. PubMed ID: 25812991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter-Reichart S; Mennel S
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study.
    Cacciamani A; Gattegna R; Pileri M; Di Nicola M; Bardanzellu S; Facciolo G; Cosimi P; Govetto A; Scarinci F
    Int Ophthalmol; 2020 Jan; 40(1):185-193. PubMed ID: 31565760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
    Schumann RG; Langer J; Compera D; Luedtke K; Schaumberger MM; Kreutzer T; Mayer WJ; Wolf A; Priglinger SG
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.
    Morescalchi F; Gambicorti E; Duse S; Costagliola C; Semeraro F
    Expert Opin Drug Saf; 2016 Sep; 15(9):1267-78. PubMed ID: 27388220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
    Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
    Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic vitreolysis in diabetic retinopathy.
    El-Asrar AM; Al-Mezain HS
    Curr Pharm Biotechnol; 2011 Mar; 12(3):406-9. PubMed ID: 20939804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flare changes after intravitreal injection of ocriplasmin in symptomatic vitreomacular traction syndrome.
    Pirani V; Pelliccioni P; Cesari C; Carrozzi G; Cavallero E; Mariotti C
    Jpn J Ophthalmol; 2019 May; 63(3):255-261. PubMed ID: 30805734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome.
    Vasquez DH; Altamirano JC; Casaus A; Del Valle RA; Gonzalez R; Gonzalez-De La Rosa A; Navarro-Partida J; Vasquez MA; Santos A
    Curr Eye Res; 2018 Feb; 43(2):208-212. PubMed ID: 29111823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications.
    Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ
    Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema.
    Sivaprasad S; Ockrim Z; Massaoutis P; Ikeji F; Hykin PG; Gregor ZJ
    Retina; 2008; 28(10):1435-42. PubMed ID: 18628722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders.
    Shaikh M; Miller JB; Papakostas TD; Husain D
    Semin Ophthalmol; 2017; 32(1):52-55. PubMed ID: 27786583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COMBINED PNEUMATIC AND ENZYMATIC VITREOLYSIS FOR SEVERE CASES OF VITREOMACULAR TRACTION.
    Yu G; Seto BK; Yamada K; Zeng K; Arroyo JG
    Retin Cases Brief Rep; 2022 Sep; 16(5):631-636. PubMed ID: 32910027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.